{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:15Z","timestamp":1782452775834,"version":"3.54.5"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite progress in understanding placebo effects in clinical trials of inflammatory bowel disease (IBD), there is a limited understanding of how socioeconomic factors of recruiting countries impact placebo rates. We investigated the association of socioeconomic factors across recruitment sites on placebo rates in IBD randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined the association of clinical and endoscopic remission and response to the weighted Gross National Index (GNI) per capita, Human Development Index (HDI), and out-of-pocket health expenditures as a percentage of current health expenditures (OOP_CHE) of identified trials using mixed effects linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across 76 trials (Crohn\u2019s disease [CD]: n\u2009=\u200932; ulcerative colitis [UC]: n\u2009=\u200944), placebo response rates over time were largely stable, with a small increase across time in clinical remission for CD trials (\u03b2\u2009=\u20090.4% per increase in study year, 95% CI: 0.3%-0.84%, P\u2009=\u2009.04) and a small decrease across time in endoscopic response for UC trials (\u03b2\u2009=\u2009\u22121.39% per increase in study year, 95% CI: \u22121.79, \u22120.99, P\u2009&amp;lt;\u2009.001). Clinical response was most susceptible to changes in socioeconomic factors in IBD trials (\u03b2\u2009=\u2009\u22122.96% per 10\u2009000 USD increase in study GNI, 95% CI: \u22124.98, \u22120.95%, P\u2009=\u2009.004; P\u2009&amp;lt;\u2009.05 for HDI and OOP_CHE). Across both conditions, decreases in clinical response were associated with increases in HDI and OOP_CHE (CD HDI: \u03b2\u2009=\u2009\u22121.15% per 0.01 increase in study HDI, 95% CI: \u22122.24, \u22120.06%, P\u2009=\u2009.04; UC HDI: \u03b2\u2009=\u2009\u22120.66% per 0.01 increase in study HDI, 95% CI: \u22121.19, \u22120.12%, P\u2009=\u2009.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We found that placebo clinical response was most susceptible to influences of site-level socioeconomic wellbeing. These findings highlight that estimation of placebo rates in trial planning should account for geographic location of recruiting sites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag081","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:20:36Z","timestamp":1780312836000},"source":"Crossref","is-referenced-by-count":0,"title":["The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials"],"prefix":"10.1093","volume":"20","author":[{"given":"Shane W","family":"Goodwin","sequence":"first","affiliation":[{"name":"Department of Medicine, London Health Science Centre Research Institute, London Health Science Centre , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-3042","authenticated-orcid":false,"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Medicine, London Health Science Centre Research Institute, London Health Science Centre , London, ON,","place":["Canada"]},{"name":"Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona , Scottsdale, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Universit\u00e0 Vita-Salute San Raffaele , Milan,","place":["Italy"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-8657","authenticated-orcid":false,"given":"Vineet","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer","family":"Kumar Vuyyuru","sequence":"additional","affiliation":[{"name":"Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shehab","sequence":"additional","affiliation":[{"name":"Program of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University , Khaldiya,","place":["Kuwait"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Center , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Western University , London, ON,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062600535890000_jjag081-B1","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/ibd\/izac240","article-title":"How to minimize placebo response and remission rates","volume":"29","author":"Ainsworth","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026062600535890000_jjag081-B2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrgastro.2015.117","article-title":"Placebo effects and their determinants in gastrointestinal disorders","volume":"12","author":"Elsenbruch","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026062600535890000_jjag081-B3","doi-asserted-by":"publisher","first-page":"641436","DOI":"10.3389\/fphar.2021.641436","article-title":"The placebo and nocebo responses in clinical trials in inflammatory bowel diseases","volume":"12","author":"Enck","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026062600535890000_jjag081-B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011572.pub2CD011572","article-title":"Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis","volume":"9","author":"Jairath","year":"2017","journal-title":"Cochrane Database Sys Rev."},{"key":"2026062600535890000_jjag081-B5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/ibd\/izad052","article-title":"Endoscopic and histological response rates in Crohn\u2019s disease clinical trials: a systematic review and meta-analysis","volume":"30","author":"Vuyyuru","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026062600535890000_jjag081-B6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2024.10.009","article-title":"Placebo rates in Crohn\u2019s disease randomized clinical trials: an individual patient data meta-analysis","volume":"168","author":"Solitano","year":"2025","journal-title":"Gastroenterol"},{"key":"2026062600535890000_jjag081-B7","doi-asserted-by":"publisher","first-page":"jjaf191","DOI":"10.1093\/ecco-jcc\/jjaf191","article-title":"Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis","volume":"19","author":"Solitano","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026062600535890000_jjag081-B8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/art.43302","article-title":"Global recruiting patterns affect placebo response rates in clinical trials of psoriatic arthritis and plaque psoriasis","volume":"78","author":"Kerschbaumer","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026062600535890000_jjag081-B9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.ard.2025.07.010","article-title":"Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis","volume":"84","author":"Kerschbaumer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026062600535890000_jjag081-B10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/epi.18197","article-title":"Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy","volume":"66","author":"Kerr","year":"2025","journal-title":"Epilepsia"},{"key":"2026062600535890000_jjag081-B11","volume-title":"Measuring Disparities in Health Status and in Access and Use of Healthcare in OECD Countries","author":"de Looper","year":"2009"},{"key":"2026062600535890000_jjag081-B12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterol"},{"key":"2026062600535890000_jjag081-B13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1053\/j.gastro.2025.08.032","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn\u2019s disease: 2025 AGA evidence synthesis","volume":"169","author":"Singh","year":"2025","journal-title":"Gastroenterol"},{"key":"2026062600535890000_jjag081-B14","author":"The World Bank, World Development Indicators","year":"2012"},{"key":"2026062600535890000_jjag081-B15","volume-title":"Human Development Report 1990","author":"UNDP","year":"1990"},{"key":"2026062600535890000_jjag081-B16","volume-title":"National Accounts of OECD Countries, 2022","author":"Organisation for Economic Co-operation and Development (OECD)","year":"2023"},{"key":"2026062600535890000_jjag081-B17","volume-title":"R: A Language and Environment for Statistical Computing.","author":"R4.3 R Core Team","year":"2021"},{"key":"2026062600535890000_jjag081-B18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ibd\/izz241","article-title":"Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s disease","volume":"26","author":"Lewis","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026062600535890000_jjag081-B19","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026062600535890000_jjag081-B20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026062600535890000_jjag081-B21","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v23.i34.6294","article-title":"Access to biologicals in Crohn\u2019s disease in ten European countries","volume":"23","author":"Pentek","year":"2017","journal-title":"World J Gas\u00adtroenterol"},{"key":"2026062600535890000_jjag081-B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1015\/S2468-1253(25)00346-2","article-title":"Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease","volume":"11","author":"Shebab","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062600535890000_jjag081-B23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/picr.picr_109_24","article-title":"Clinical trial footprint in BRICS: Improvements seen but needs further affirmative action","volume":"15","author":"Davis","year":"2024","journal-title":"Perspect Clin Res"},{"key":"2026062600535890000_jjag081-B24","doi-asserted-by":"publisher","first-page":"17562848231174290","DOI":"10.1177\/17562848231174290","article-title":"Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis","volume":"16","author":"Prokopic","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"2026062600535890000_jjag081-B25","doi-asserted-by":"publisher","first-page":"P2102","DOI":"10.1016\/j.cgh.2024.12.007","article-title":"Differential efficacy of advanced therapies in inducing remission in ulcerative colitis based on prior exposure to TNF antagonists","volume":"23","author":"Lee","year":"2025","journal-title":"Clin Gastro Hep"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag081\/68624588\/jjag081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag081\/68624588\/jjag081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:54:12Z","timestamp":1782449652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag081\/8718667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag081","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"jjag081"}}